The Treatment of Antisocial Personality Disorder

被引:0
|
作者
Black D.W. [1 ]
机构
[1] Department of Psychiatry, University of Iowa Carver College of Medicine, 2-126b MEB/Psychiatry Research, Iowa City, 52242, IA
关键词
Antidepressants; Antipsychotics; Antisocial personality disorder; Cognitive-behavioral therapy; Mood stabilizers; Sociopathy;
D O I
10.1007/s40501-017-0123-z
中图分类号
学科分类号
摘要
Purpose of Review Antisocial personality disorder (ASPD) is defined by its pattern of socially irresponsible, exploitative, and guiltless behavior. The disorder is common and costly to society. ASPD starts in childhood or early adolescence when it is diagnosed as conduct disorder. If the symptoms persist past age 18, the diagnosis changes to ASPD. The disorder moderates with advancing age and many individuals will no longer meet criteria for the disorder as older adults. Recent Findings The treatment of ASPD is challenging and complicated by a dearth of research evidence. There are no medications approved by the US Food and Drug Administration for treatment of the disorder, nor are there proven psychological treatments. Medications can be prescribed to treat comorbid disorders (e.g., panic disorder, major depression), or “off-label” to target aggression and impulsivity associated with ASPD. Treatment models employing cognitive-behavioral therapy have been developed, and some reports suggest benefit. Summary Patients with ASPD should not routinely be treated with psychotropic medication. Medications may be helpful in treating comorbid psychiatric disorders such as major depression, or aggressive symptoms common in these patients. Cognitive-behavior therapy may be helpful for those with milder syndromes. © 2017, Springer International Publishing AG.
引用
收藏
页码:295 / 302
页数:7
相关论文
共 50 条
  • [41] Pharmacological interventions for antisocial personality disorder
    Khalifa, Najat R.
    Gibbon, Simon
    Voellm, Birgit A.
    Cheung, Natalie H-Y
    McCarthy, Lucy
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (09):
  • [42] Neurocognitive function in antisocial personality disorder
    Dinn, WM
    Harris, CL
    PSYCHIATRY RESEARCH, 2000, 97 (2-3) : 173 - 190
  • [43] Antisocial personality disorder: an epidemiological perspective
    Herman, H
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2000, 34 (03): : 548 - 549
  • [44] Antisocial Personality Disorder: A Current Review
    Glenn, Andrea L.
    Johnson, Alexandria K.
    Raine, Adrian
    CURRENT PSYCHIATRY REPORTS, 2013, 15 (12)
  • [45] Psychological interventions for antisocial personality disorder
    Gibbon, Simon
    Khalifa, Najat R.
    Cheung, Natalie H-Y
    Voellm, Birgit A.
    McCarthy, Lucy
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (09):
  • [46] Dysfunctional beliefs and antisocial personality disorder
    McMurran, Mary
    Christopher, Gary
    JOURNAL OF FORENSIC PSYCHIATRY & PSYCHOLOGY, 2008, 19 (04): : 533 - 542
  • [47] Correction to: Monoamine Oxidase a in Antisocial Personality Disorder and Borderline Personality Disorder
    Nathan J. Kolla
    Sarah A. Vinette
    Current Behavioral Neuroscience Reports, 2018, 5 (1) : 124 - 124
  • [48] Psychopathy/antisocial personality disorder conundrum
    Ogloff, James R. P.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2006, 40 (6-7): : 519 - 528
  • [49] Antisocial personality disorder: A biopsychosocial model
    Paris, J
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1996, 41 (02): : 75 - 80
  • [50] Locus of control in antisocial personality disorder
    Turkcapar, MH
    Ozel, A
    Guriz, O
    Isik, B
    COGNITIVE PSYCHOTHERAPY TOWARD A NEW MILLENNIUM: SCIENTIFIC FOUNDATIONS AND CLINICAL PRACTICE, 2002, : 381 - 384